No title
Prostate cancer is one of the most frequent cancers in males in Western countries. Radical prostatectomy serves as the first line of treatment for patients with localised prostate cancer. However, in many cases the cancer will recur. It is currently difficult to identify those patients at a high risk of tumour recurrence. Therefore, molecular markers associated with and predicting disease recurren
